CDSCO Panel Approves Eli Lilly's Protocol Amendment Proposal for Antidiabetic Drug Retatrutide study
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...
This time last year, people were still bickering about whether Novo Nordisk's Wegovy and Eli Lilly & Co.'s Zepbound represented a shortcut to losing weight or a medical breakthrough. But with reams of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback